openPR Logo
Press release

Human Immunodeficiency Virus (HIV)-1 Therapeutics Industry Vendors- Gilead Sciences, AbbVie, Bristol-Myers Squibb Company, ViiV Healthcare, and Cipla

11-14-2017 01:06 PM CET | Health & Medicine

Press release from: Global Market Insights, Inc.

Global Market Insights, Inc.

Global Market Insights, Inc.

The research report “Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, Industry Analysis Report, Regional Outlook (U.S., Canada, UK, Germany, France, Italy, Spain, Japan, China, India, Brazil, Mexico, South Africa), Application Development Potential, Price Trends, Competitive Market Share & Forecast, 2017 – 2024” by Global Market Insights, Inc. says, Human Immunodeficiency Virus (HIV)-1 Therapeutics Market size is projected to experience significant growth from 2017 to 2024.

Human Immunodeficiency Virus Therapeutics Market size should witness tremendous growth, owing to the sprouting incidence of HIV infections. The growing youth-obsessed culture across globe is mostly under the vague of HIV due to unprotected sexual practices coupled with the dearth of awareness concerning transmission risk factors as well as exposure to contaminated and infected needles or syringes. The collaborative efforts of the government and various NGOs to provide help for at-risk individuals with greater receptiveness to disease testing and treatment is the key driving factor of the human immunodeficiency virus therapeutics market. According to American Hospital Association, there were 1.5 million adults and children surviving with HIV/AIDS in North America as of 2016.

High adolescent fertility rate is the opposing effect of extramarital and premarital sex, leading to longer period of sexual activity which increases the risk of infection among the populace. The virus has mostly affected the under developed and the developing countries on a broader scale owing to the scarcity of appropriate treatment, prevention measures and facilities. Approximately 70,000 children and adults are anew infected every year. Nearly 26,000 people in North America die from AIDS every year, with only limited number of patients receive admittance to antiretroviral treatments.

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/1949

Programs such as Medicare and Medicaid initiated by the U.S. government assists the low-income people in medical billing. The largest HIV specific discretionary grant program is the Ryan White HIV Program which serves as the third biggest source of federal funding for HIV treatment and care in the U.S. The NRTIs (first type of drug available to treat HIV) accounted for the largest market share. It works by blocking the reverse transcriptase enzyme as well as arrests viral replication and impede reverse transcriptase activity.

Integrase inhibitors product segment will witness fastest growth, due to the rise in added integrase inhibitors by key players such as Merck & Co. and Gilead Sciences. These enzymes replicate by inserting viral genomic DNA into the host chromosome. The recent discovery in this segment is the quinoline-based allosteric IN inhibitors (ALLINIs), which potently impairs HIV-1 replication and are presently in clinical trials.

Browse key industry insights from the report Human Immunodeficiency Virus (HIV)-1 Therapeutics Market in detail along with the table of contents:

https://www.gminsights.com/industry-analysis/human-immunodeficiency-virus-hiv-1-therapeutics-market

Social stigma, decreasing global funds, discrimination and treatment failures are few factors hindering the growth of the global human immunodeficiency virus therapeutics market. Lack of a definitive treatment is a key health issue and results in a high on-going cost to society.
North America human immunodeficiency virus therapeutics market dominated the industry in 2016 pertaining to the high incidence and prevalence of HIV/AIDS, growing awareness about infection, surging government initiatives and blood donations. The U.S. human
immunodeficiency virus therapeutics market is commanded as the greatest national funder of the HIV epidemic globally.

Request for TOC for this report @ https://www.gminsights.com/request-toc/upcoming/1949

Asia Pacific human immunodeficiency virus therapeutics market will exhibit profitable growth, owing to new developments in treatments. Asian manufacturers prove to be a resilient competition due to their unique patent laws that lead up patent of prerequisite lifesaving medicines. Also, the prices are doomed to decrease the entry of such manufacturers, thereby potentially proliferating the industry with regards to volume.

Key industry players include Gilead Sciences, AbbVie, Bristol-Myers Squibb Company, ViiV Healthcare, and Cipla. Companies focus on innovative product launch and strategic agreements to expand their business portfolio as main strategies. In April 2016, Gilead Sciences, announced the FDA approval of Descovy, a fixed-dose combination for the treatment of HIV, for the treatment of HIV-1 infection.

Browse Related Reports:

HIV Diagnostics Market Size By Product [Antibody Tests (HIV-1 Screening, ELISA/EIA, Home Access Dried Blood Spot, Rapid Test, HIV-1 Confirmatory Steps, Western Blot, Indirect Immunoflorescent Antibody Assay (IIFA), Line Immunoassay , RadioImmuno Precipitation Assay (RIPA), HIV-2 & Group O Test, Blood Antibody, Dried Blood Spot), Viral Identification Assay (p24 Antigen, Qualitative PCR, Viral Culture), CD4, Viral Load, Early Infant Diagnosis], Industry Analysis Report, Regional Outlook (U.S., Canada, UK, Germany, Japan, China, South Africa, Brazil), Application Potential, Price Trends, Competitive Market Share & Forecast, 2016 – 2023

https://www.gminsights.com/industry-analysis/hiv-diagnostics-market

About Global Market Insights:

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

Contact Us:

Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com
Web: https://www.gminsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Human Immunodeficiency Virus (HIV)-1 Therapeutics Industry Vendors- Gilead Sciences, AbbVie, Bristol-Myers Squibb Company, ViiV Healthcare, and Cipla here

News-ID: 816208 • Views:

More Releases from Global Market Insights, Inc.

Rare Sugar Market Top 3 Trends, Covid-19 Outbreak, Factors Driving, Threats, Cha …
Rising awareness regarding health & fitness and the subsequent shift in consumer trends towards low-calorie sweeteners will boost rare sugar market share over the forecast spell. Recent years have marked a steady rise in the prevalence of cardiovascular ailments, diabetes, and obesity, among other chronic conditions, which have triggered a massive change in consumer perceptions towards health. This in turn has led to a surge in demand for various functional foods
Global Selenium Yeast Market Industry Assessment, Trends, Competitive Landscape, …
The selenium yeast market is anticipated to register substantial gains on account of rising inclination towards organic additives in animal nutrition, with an aim to improve livestock health and production. Consumers are steadily becoming aware of the downsides associated with using synthetic additives. As a result, they are preferring selenium yeast feed grades over other counterparts to provide balanced nutrition to their livestock. According to Global Market Insights Inc estimates
Power Distribution Component Market Share, Size, Trends by 2025 | Leading Key players Eaton, Schneider, Siemens, Hitachi, Powell, Hubbell
Power Distribution Component Market Share, Size, Trends by 2025 | Leading Key pl …
Global Power Distribution Component Market Report offers market overview, segmentation by types, application, countries, key manufactures, cost analysis, industrial chain, sourcing strategy, downstream buyers, marketing strategy analysis, distributors/traders, factors affecting market, forecast and other important information for key insight. Request a sample of this research report @ https://www.gminsights.com/request-sample/detail/3091 Voltage rating have acted as a standard industry protocol toward the installation of power components reliant on regulatory preference, deployment areas, and the group
Prenatal Vitamin Ingredients Market New Entrants, Risk Factors, Market Expansion …
The rise in the instances of miscarriages on account of poor diet and hygiene will anchor the consumption of prenatal vitamin ingredients. Excessive intake of junk food has resulted in the scarcity of important nutrients in pregnant women that could adversely affect the fetus health and development. Furthermore, prenatal vitamin ingredients possess additional nutritional components that are not so easily sourced from regular food items and products. Prenatal vitamin ingredients can

All 5 Releases


More Releases for HIV

HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Introduction to Human Immunodeficiency Virus (HIV) Vaccines 1.1 Overview 1.2 Antiquity of HIV Vaccine Need for the Development of HIV Vaccine Primer of HIV inside the Body 3.1 Inclusion of HIV Virus into the System 3.2 Interaction of HIV with Host 3.3 Eradication of HIV Virus HIV Vaccine Development Process 4.1 Introduction
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways
Hidden HIV Revealed: New Insights Into Latent HIV Infections
In spite of ever more effective therapies, HIV keeps managing to survive in the body. A comprehensive project conducted by the Austrian Science Fund FWF has clarified the molecular processes which contribute to this effect. In the process, approaches were discovered for possible therapies to combat the hidden reservoir formed by the virus. Thanks to modern therapies, HIV infections have become controllable – but these treatments cannot provide a cure. Antiretroviral